Publications by authors named "Beatriz G Serelde"

Article Synopsis
  • Zalypsis(®) is undergoing phase II trials for multiple cancers, but its effectiveness varies among patients and identifying biomarkers could enhance treatment targeting.
  • Researchers created molecular profiles from sarcoma cell lines to predict Zalypsis sensitivity, tested them in lab cultures, and evaluated them in animal models.
  • Resistance to Zalypsis was linked to elevated levels of certain receptor tyrosine kinases (TKRs), suggesting that understanding RTK activation could improve patient selection for future clinical trials.
View Article and Find Full Text PDF

Inhibitors of PI3K signaling are of great therapeutic interest in oncology. The phosphoinositide-3-kinase signaling pathway is activated in a variety of solid and non-solid tumors. We have identified an imidazopyrazine derivative, ETP-46321, as a potent inhibitor of PI3Kα [Formula: see text].

View Article and Find Full Text PDF

Here we report the development and validation of a complete solution to manage and analyze the data produced by image-based phenotypic screening campaigns of small-molecule libraries. In one step initial crude images are analyzed for multiple cytological features, statistical analysis is performed and molecules that produce the desired phenotypic profile are identified. A naïve Bayes classifier, integrating chemical and phenotypic spaces, is built and utilized during the process to assess those images initially classified as "fuzzy"-an automated iterative feedback tuning.

View Article and Find Full Text PDF

Activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is one the most frequent genetic events in human cancer. A cell-based imaging assay that monitored the translocation of the Akt effector protein, Forkhead box O (FOXO), from the cytoplasm to the nucleus was employed to screen a collection of 33,992 small molecules. The positive compounds were used to screen kinases known to be involved in FOXO translocation.

View Article and Find Full Text PDF
Article Synopsis
  • Aplidin (plitidepsin) is an anticancer drug derived from a marine organism, showing strong anti-tumor potential in preclinical trials and is currently in phase II clinical trials for various cancers.
  • Aplidin works by inducing oxidative stress in tumor cells, leading to the activation of specific protein kinases, although its complete mechanism of action is not fully understood.
  • The effectiveness of Aplidin is linked to levels of the protein p27; lower levels of p27 enhance sensitivity to the drug, making it a potential predictor of patient response in ongoing clinical studies.
View Article and Find Full Text PDF
Article Synopsis
  • Yondelis (Trabectedin) is being tested for its effectiveness against advanced soft tissue sarcoma in patients who have already undergone treatment.
  • Researchers created several tumor cell lines from untreated sarcoma patients to analyze how sensitive or resistant these cells were to Trabectedin and another chemotherapy drug, doxorubicin.
  • The study found that some cell lines were resistant to Trabectedin, but this resistance did not relate to doxorubicin resistance, and mutations or deletions in the p53 gene were linked to heightened sensitivity to Trabectedin.
View Article and Find Full Text PDF